Your browser is no longer supported. Please, upgrade your browser.
Settings
EDIT Editas Medicine, Inc. daily Stock Chart
EDIT [NASD]
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-2.99 Insider Own2.80% Shs Outstand48.06M Perf Week2.40%
Market Cap1.70B Forward P/E- EPS next Y-3.50 Insider Trans-11.32% Shs Float40.06M Perf Month-5.23%
Income-120.30M PEG- EPS next Q-0.82 Inst Own75.80% Short Float15.68% Perf Quarter16.36%
Sales13.70M P/S124.01 EPS this Y1.10% Inst Trans1.23% Short Ratio3.97 Perf Half Y55.11%
Book/sh4.88 P/B7.24 EPS next Y-4.50% ROA-32.60% Target Price44.74 Perf Year82.03%
Cash/sh6.85 P/C5.16 EPS next 5Y- ROE-61.90% 52W Range13.12 - 45.02 Perf YTD15.03%
Dividend- P/FCF- EPS past 5Y- ROI-48.20% 52W High-21.15% Beta-
Dividend %- Quick Ratio9.10 Sales past 5Y- Gross Margin- 52W Low170.58% ATR2.29
Employees112 Current Ratio9.10 Sales Q/Q311.10% Oper. Margin- RSI (14)53.17 Volatility4.40% 6.67%
OptionableYes Debt/Eq0.20 EPS Q/Q22.90% Profit Margin- Rel Volume0.47 Prev Close35.35
ShortableYes LT Debt/Eq0.16 EarningsMar 06 AMC Payout- Avg Volume1.58M Price35.50
Recom2.70 SMA202.91% SMA50-1.65% SMA20031.52% Volume385,469 Change0.42%
Feb-13-18Initiated CLSA Underperform
Jan-23-18Upgrade SunTrust Hold → Buy
Jul-14-17Initiated SunTrust Hold $17
Mar-28-17Initiated Chardan Capital Markets Buy $65
Aug-10-16Upgrade Jefferies Hold → Buy
Jun-02-16Initiated Jefferies Hold
Feb-29-16Initiated Morgan Stanley Equal-Weight $28
Feb-29-16Initiated JP Morgan Neutral
Feb-29-16Initiated JMP Securities Mkt Outperform
Apr-18-18 10:29AM  Companies with women executives can help you do better in the stock market MarketWatch
Apr-03-18 09:32AM  Oops! CRISPR Concerns Turn Out to be a Big Nothingburger Motley Fool
Mar-28-18 09:00AM  Editas Medicine Names James C. Mullen as Chairman of the Board of Directors GlobeNewswire
Mar-25-18 09:31AM  3 Stocks That Could Double Your Money Motley Fool
Mar-22-18 07:30AM  New Research: Key Drivers of Growth for Editas Medicine, Magellan Health, The RMR Group, Marcus, Nordson, and USA Compression Partners, LP Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-16-18 06:13AM  3 Reasons CRISPR Stocks Could Keep Soaring Motley Fool
Mar-15-18 05:09PM  Why CRISPR Therapeutics Slipped 10% on Thursday Motley Fool -5.23%
Mar-13-18 07:57AM  Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics Zacks
07:30AM  Record Revenue Growth & Imminent Nasdaq Listing Could Spell Big Upside for Unknown Orgenesis (ORGS) ACCESSWIRE
07:20AM  Wired News Voyager Therapeutics Declared Longer-term Data from Phase-1b Trial Of VY-AADC for Advanced Parkinsons Disease ACCESSWIRE
Mar-09-18 08:01AM  Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno Zacks
Mar-08-18 04:53PM  Companies with women executives can help you do better in the stock market MarketWatch
12:25PM  Healthcare Heroes That Aren't Done Yet Zacks
12:11AM  Edited Transcript of EDIT earnings conference call or presentation 6-Mar-18 10:00pm GMT Thomson Reuters StreetEvents
Mar-07-18 05:40PM  Editas Medicine Delivers Another Strong Quarter Motley Fool +9.99%
03:49PM  Here's Why Editas Medicine Inc. Ticked Up Today Motley Fool
Mar-06-18 04:49PM  Editas reports 4Q loss Associated Press
04:01PM  Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update GlobeNewswire
01:30PM  Editas Medicine, Inc. to Host Earnings Call ACCESSWIRE
08:35AM  Editas Medicine Q4 Earnings Preview Benzinga
Mar-05-18 12:00AM  [$$] Crispr gene editing ready for testing in humans Financial Times
Mar-02-18 08:45AM  3 Growth Stocks That Could Put Facebook's Returns to Shame Motley Fool +7.54%
Mar-01-18 04:17PM  Pentagon Lab Worries About CRISPR Bioattack As China Seeks Genome Lead Investor's Business Daily
Feb-28-18 09:00AM  Editas Medicine Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases GlobeNewswire
Feb-27-18 04:01PM  Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results GlobeNewswire
Feb-23-18 12:29PM  3 Top DNA Stocks to Consider Buying Now Motley Fool
10:31AM  Gilead's Latest Deal Is Good News for Biotechs Barrons.com
07:40AM  Orgenesis (ORGS): An Undervalued Small Cap Biotech Company Every Healthcare Investor Should Know About ACCESSWIRE
Feb-16-18 09:00AM  Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors GlobeNewswire
Feb-15-18 06:02AM  3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate Motley Fool
Feb-08-18 04:01PM  Editas Medicine to Participate in Upcoming Investor Conferences GlobeNewswire -9.24%
Feb-05-18 07:04AM  All the Stocks I'm Selling If the Market Keeps Falling Motley Fool
Feb-02-18 03:10PM  Can CRISPR And These 3 Small Biotechs Cure 10,000 Diseases? Investor's Business Daily
Jan-30-18 12:03PM  Here's Why Editas Medicine Rose as Much as 15.7% Yesterday Motley Fool
08:33AM  Editas Medicine (EDIT) Surges: Stock Moves 13.2% Higher Zacks
Jan-27-18 10:32AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-25-18 04:00PM  Adverum Biotechnologies and Editas Medicine Extend Research Collaboration GlobeNewswire
Jan-24-18 08:00AM  Celgene's Been Selling Shares in This Biotech Motley Fool
Jan-23-18 03:50PM  2 Gene Editing Stocks SunTrust Recommends Benzinga
09:48AM  Forget Penny Stocks: Your Money Is Better Off in These 3 Companies Motley Fool
Jan-22-18 04:27PM  Here's Why Editas Medicine Gained as Much as 14.2% Today Motley Fool +13.88%
07:30AM  Market Trends Toward New Normal in Editas Medicine, Impinj, Neos Therapeutics, Nordson, National Western Life Group, and Square Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-16-18 07:34AM  CRISPR Gene-Editing Stocks Going Down the Tubes? Think Again Motley Fool -6.19%
Jan-08-18 01:49PM  Editas lower on questions about Crispr efficacy CNBC Videos -10.63%
09:00AM  Editas Medicine Reports on Recent Progress and Announces EM22 Five-year Goals at J.P. Morgan Healthcare Conference GlobeNewswire
08:52AM  What Should We Expect From Editas Medicine Incs (NASDAQ:EDIT) Earnings In The Years Ahead? Simply Wall St.
08:00AM  Uh-Oh! CRISPR Gene-Editing Stocks May Be Worthless Motley Fool
07:07AM  3 Soaring Gene-Editing Biotech Stocks: Which Is the Best Buy? Motley Fool
Jan-03-18 08:57AM  Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-02-18 04:51PM  Is This Why Editas Medicine Is Surging Today? Motley Fool +11.68%
Dec-27-17 07:30PM  3 Stocks That Feel Like Netflix in 2002 Motley Fool
02:35PM  Want To Invest In Editas Medicine Inc (NASDAQ:EDIT)? Heres How It Performed Lately Simply Wall St.
Dec-26-17 06:04AM  3 Stocks That Could Make You Rich Motley Fool
Dec-22-17 12:32PM  CRISPR Therapeutics Stock Wins a Buy Rating: What You Need to Know Motley Fool +6.44%
03:00AM  Editas Medicine Joins Elite Club Of Stocks With RS Ratings Over 90 Investor's Business Daily
Dec-19-17 12:50PM  ETFs with exposure to Editas Medicine, Inc. : December 19, 2017 Capital Cube
Dec-12-17 08:07AM  Editas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : December 12, 2017 Capital Cube
Dec-11-17 06:00PM  Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia GlobeNewswire -5.45%
Dec-06-17 11:44AM  Here's Why Editas Medicine Inc. Stock Is Slipping Today Motley Fool -7.75%
07:00AM  Editas Medicine, Inc., Announces Pricing of $50 Million Offering of Common Stock GlobeNewswire
Dec-05-17 04:17PM  Editas Medicine, Inc., Announces Offering of Common Stock GlobeNewswire
Nov-30-17 03:58PM  Here's Why Sangamo Therapeutics Rose as Much as 14.9% Thursday Motley Fool
Nov-22-17 01:15PM  FDA warns against do it yourself gene therapy kits American City Business Journals +8.86%
Nov-14-17 07:34AM  Disruptor Alert: These 5 Companies Are Changing Healthcare Motley Fool
07:00AM  Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team PR Newswire
Nov-13-17 05:26PM  Edited Transcript of EDIT earnings conference call or presentation 7-Nov-17 10:00pm GMT Thomson Reuters StreetEvents
Nov-09-17 09:00AM  Editas Medicine Keeps Moving Forward Motley Fool
07:53AM  Editas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : November 9, 2017 Capital Cube
Nov-08-17 04:24PM  Barclays: Editas Medicine On Track To File New Drug App Next Year Benzinga
12:25PM  Here's Why Editas Medicine Collapsed at Market Open Today Motley Fool
Nov-07-17 04:13PM  Editas reports 3Q loss Associated Press
04:03PM  Editas Medicine Announces Third Quarter 2017 Results and Update GlobeNewswire
03:48PM  Editas CEO to testify at U.S. Senate hearing on gene editing potential, ethics American City Business Journals
07:03AM  What Investors Should Know About Editas Medicine Incs (EDIT) Financial Strength Simply Wall St.
Nov-03-17 08:00AM  Editas Medicine to Host Conference Call Discussing Third Quarter 2017 Corporate Update and Results GlobeNewswire
Oct-31-17 12:09PM  Editas Medicine, Inc. Value Analysis (NASDAQ:EDIT) : October 31, 2017 Capital Cube
11:37AM  ETFs with exposure to Editas Medicine, Inc. : October 31, 2017 Capital Cube
Oct-30-17 08:11AM  Editas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : October 30, 2017 Capital Cube +7.27%
Oct-19-17 12:45PM  Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic Mice GlobeNewswire
Oct-03-17 08:00AM  Editas Medicine to Participate in Investor Conferences in October GlobeNewswire
Oct-02-17 04:10PM  Why Bluebird's Downgrade Sent These Two Rivals Skyrocketing Investor's Business Daily
Sep-27-17 09:46AM  Axovant Rises After Tuesday's Plunge - Biotech Movers TheStreet.com
Sep-26-17 04:01PM  Editas Medicine Receives EMAs Orphan Medicinal Product Designation for EDIT-101 for the Treatment of LCA10 GlobeNewswire
Sep-12-17 08:00AM  Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10) GlobeNewswire
Sep-07-17 09:30PM  Why Gene-Editing Pioneer Editas Skyrocketed 28.8% in August Motley Fool
Sep-05-17 08:00AM  Editas Medicine to Participate in Morgan Stanley 15th Annual Global Healthcare Conference GlobeNewswire
Aug-31-17 11:29AM  How a CRISPR, gene-editing technology, patent ruling could move stocks Harvest Exchange
Aug-20-17 02:02PM  This Stock Could Be the Tesla of Healthcare Motley Fool
Aug-14-17 08:16PM  Edited Transcript of EDIT earnings conference call or presentation 9-Aug-17 9:00pm GMT Thomson Reuters StreetEvents +5.51%
08:15AM  Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3% Zacks
07:30AM  [$$] Gormley's Take: Biotech Companies Are Steering Clear of Gene Editing's Ethical Concerns The Wall Street Journal
Aug-13-17 07:06AM  Edited Transcript of EDIT earnings conference call or presentation 15-May-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-09-17 10:02PM  Editas reports 2Q loss Associated Press
04:03PM  Editas Medicine Announces Second Quarter 2017 Results and Update GlobeNewswire
04:01PM  Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment GlobeNewswire
Aug-08-17 09:56AM  Here's Why Editas Medicine Rose as Much as 15.9% Monday Motley Fool
Aug-07-17 08:00AM  Editas Medicine to Host Conference Call Discussing Second Quarter 2017 Corporate Update and Results GlobeNewswire +9.09%
Jul-31-17 08:36AM  Editas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : July 31, 2017 Capital Cube
Jul-24-17 03:34PM  ETFs with exposure to Editas Medicine, Inc. : July 24, 2017 Capital Cube
Jul-18-17 09:31AM  Should You Buy Into the Hype Surrounding These Stocks? Motley Fool -5.10%
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bosley KatrinePresident and CEOApr 02Sale32.168,333267,9691,310,298Apr 04 04:05 PM
Hack Andrew A. F.Chief Financial OfficerMar 20Option Exercise20.7228,000580,08022,000Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 20Sale37.8628,0001,059,9600Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 19Option Exercise6.486,00038,8806,000Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 19Sale37.656,000225,9000Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 16Option Exercise6.486,00038,8806,000Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 16Sale39.436,000236,5800Mar 20 05:36 PM
Bosley KatrinePresident and CEOMar 09Sale45.009,134411,0301,318,631Mar 13 08:45 AM
Bosley KatrinePresident and CEOMar 01Sale35.728,333297,6931,327,765Mar 05 04:52 PM
Hack Andrew A. F.Chief Financial OfficerFeb 16Option Exercise6.486,00038,8806,000Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 16Sale35.326,000211,9200Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 15Option Exercise6.486,00038,8806,000Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 15Sale34.616,000207,6600Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 14Option Exercise6.486,00038,8806,000Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 14Sale32.716,000196,2600Feb 16 04:04 PM
Bosley KatrinePresident and CEOFeb 01Sale36.188,333301,4511,336,098Feb 05 06:05 PM
Bosley KatrinePresident and CEOJan 30Sale40.0510,000400,5201,344,431Jan 31 04:18 PM
Bosley KatrinePresident and CEOJan 29Sale37.5310,000375,3401,354,431Jan 31 04:18 PM
Bosley KatrinePresident and CEOJan 23Sale35.283,338117,7651,364,431Jan 25 04:11 PM
Bosley KatrinePresident and CEOJan 03Sale35.046,662233,4161,367,769Jan 04 04:09 PM
Bosley KatrinePresident and CEOJan 02Sale33.448,333278,6371,374,431Jan 04 04:09 PM
Hack Andrew A. F.Chief Financial OfficerDec 19Option Exercise3.234,64915,0164,649Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 19Sale25.064,649116,5100Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 18Option Exercise3.235,00016,1505,000Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 18Sale24.685,000123,4090Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 15Option Exercise3.235,00016,1505,000Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 15Sale24.315,000121,5460Dec 19 04:38 PM
Bosley KatrinePresident and CEODec 01Sale29.588,333246,5221,382,764Dec 05 06:08 AM
Hack Andrew A. F.Chief Financial OfficerNov 20Option Exercise3.235,00016,1505,000Nov 21 04:04 PM
Hack Andrew A. F.Chief Financial OfficerNov 20Sale25.355,000126,7320Nov 21 04:04 PM
Hack Andrew A. F.Chief Financial OfficerNov 17Option Exercise3.235,00016,1505,000Nov 21 04:04 PM
Hack Andrew A. F.Chief Financial OfficerNov 17Sale24.815,000124,0730Nov 21 04:04 PM
Bosley KatrinePresident and CEONov 01Sale23.648,333196,9661,391,097Nov 03 04:48 PM
Bosley KatrinePresident and CEOOct 02Sale24.788,333206,5251,399,430Oct 04 04:30 PM
Bosley KatrinePresident and CEOSep 05Sale20.206,666134,6811,407,763Sep 06 05:05 PM
Bosley KatrinePresident and CEOSep 01Sale20.4210,000204,1501,414,429Sep 06 05:05 PM
Bosley KatrinePresident and CEOAug 11Sale20.026,666133,4501,424,429Aug 14 04:35 PM
Bosley KatrinePresident and CEOAug 10Sale20.0210,000200,1601,431,095Aug 14 04:35 PM
Cox Gerald FrankChief Medical OfficerJun 02Buy14.154,00056,6004,000Jun 06 04:12 PM
Nikolic BorisDirectorJun 02Buy14.0735,000492,52735,000Jun 06 04:09 PM
Bitterman KevinDirectorMay 22Sale17.001,000,00017,000,0002,797,144May 24 04:38 PM